The recent downturn of Bellevue Group, a Zurich-based financial boutique, highlights the uncertain trajectory of the biotech sector within the healthcare industry. Despite representing only 10% of the S&P 500 index, healthcare stocks have been grappling with a Price-to-Earnings (P/E) ratio beneath the market average. Bellevue Group, once a thriving entity, now finds itself in […]